Avadel Pharmaceuticals PLC

Avadel Pharmaceuticals — Q1 2025 Earnings Presentation

16 slides from Avadel Pharmaceuticals's earnings presentation, May 7, 2025

  1. Slide 1: Avadel Pharmaceuticals plc First Quarter 2025 Earnings Slides

    AVADEL Pharmaceuticals plc (NASDAQ: AVDL) First Quarter 2025 Earnings Slides

  2. Slide 2: Transforming Medicines to Transform Lives

    A BIOPHARMACEUTICAL COMPANY FOCUSED ON TRANSFORMING MEDICINES TO TRANSFORM LIVES 2

  3. Slide 3: Safe Harbor Statements

    Safe Harbor Statements This presentation may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements relate to our future expectations, beliefs, plans, strategies, obje

  4. Slide 4: AVDL

    ~$250M Revenue Since Launch* Corporate Headquarters Publicly traded on Dublin, Ireland NASDAQ since 1996 : AVDL ~2,800 Patients on therapy* St. Louis, US Operations Missouri Deep, wholly-owned pipeline with Management team with extensive numerous expansion opportunities commercial experience in rare

  5. Slide 5: Avadel Pharmaceuticals First Quarter 2025 Highlights

    Avadel Pharmaceuticals First Quarter 2025 Highlights Commercial Investments Enrollment Remains Robust Well-Capitalized to Support Accelerated LUMRYZ Launch in Phase 3 REVITALYZ Trial in Launch and Ongoing LCM* in Narcolepsy Idiopathic Hypersomnia Programs Generated $52.5 million in net revenue, 42,0

  6. Slide 6: 2025 Launch Investments Accelerating LUMRYZ Uptake and Persistency

    2025 Launch Investments Accelerating LUMRYZ Uptake and Persistency Launch Investments: Early Impact: Salesforce expansion has yielded Raised FY25 LUMRYZ growth in new patient enrollments revenue guidance across all patient types – driven primarily by new LUMRYZ writers Raised FY25 patients on therap

  7. Slide 7: LUMRYZ Peak Sales Opportunity is >$1B For Narcolepsy

    LUMRYZ Peak Sales Opportunity is >$1B For Narcolepsy >14K patients currently treated with Over 50K oxybate-eligible patients >14,000 first-generation with narcolepsy patients oxybates >15K patients 25,000+ patients >50,000 who discontinued first- 8K reimbursed patients on therapy achieves $1B in sal

  8. Slide 8: Laser-Focused on the Levers That Propel LUMRYZ's $1B Opportunity in Narcolepsy

    Laser-Focused on the Levers That Propel LUMRYZ’s $1B Opportunity in Narcolepsy1 >2K Reimbursed Accelerate our investments to drive patients on therapy demand from all patient types and further as of 3/31/25 unlock switch patient opportunity Drive improvements in persistency, especially with new to o

  9. Slide 9: Idiopathic hypersomnia (IH) is a rare sleep disorder

    Idiopathic hypersomnia (IH) is a rare sleep disorder characterized by excessive daytime sleepiness (EDS) not attributable to any other ~10% treated medical conditions; 42,000 patients with the only FDA diagnosed with IH in US approved oxybate treatment Initiated REVITALYZ Phase 3 trial to evaluate t

  10. Slide 10: Advancing Innovative and Transformative Sleep Medicine Pipeline

    Advancing Innovative and Transformative Sleep Medicine Pipeline REGULATORY PROGRAM INDICATION PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL MAJOR MILESTONES REVIEW Narcolepsy – Excessive Daytime Received FDA approval Sleepiness (EDS) and ODE in May 2023; and/or Cataplexy in launched in June 2023 Ad

  11. Slide 11: Financials

    Financials

  12. Slide 12: Financial Summary

    Financial Summary1 Q1 ($ in millions) 2024 2025 Product Revenue $27.2 $52.5 Operating Expenses $51.7 $49.9 Operating Loss ($26.0) ($3.0) Cash, Cash Equivalents & $88.8 $66.5 Marketable Securities 1 – Refer to Forms 10-Q for the periods ended March 31, 2024 and 2025 for full financial results. 12

  13. Slide 13: GAAP vs. Non-GAAP Reconciliation

    GAAP vs. Non-GAAP Reconciliation Q1 ($ in millions) 2024 2025 GAAP Operating Loss ($26.0) ($3.0) Stock Based Compensation $5.4 $4.2 Depreciation & Amortization 1 $1.1 $0.8 Transaction Costs 2 $0.5 $- Non-GAAP Operating (Loss) ($19.0) $2.0 Income 1) Includes depreciation of fixed assets and amortizat

  14. Slide 14: Revised 2025 Guidance

    Revised 2025 Guidance Current Guidance Prior Guidance Revenue $255 - $265M $240 - $260M Cash Operating Expenses $180 - $200M $180 - $200M Cash Flow $30 - $40M $20 - $40M Patients on Therapy at 12/31/2025 3.4 – 3.6K 3.3 – 3.5K 14

  15. Slide 15: A Leader in the Sleep Space With Substantial Growth Opportunities

    A Leader in the Sleep Space With Substantial Growth Opportunities Meeting Unmet Needs in Narcolepsy 94%1 of patients prefer LUMRYZ over first-generation oxybates due to once at night dosing; awarded Orphan Drug Exclusivity for major contribution to patient care Opportunity For Growth In Narcolepsy $

  16. Slide 16: AVADEL Pharmaceuticals plc

    AVADEL Pharmaceuticals plc (NASDAQ: AVDL) First Quarter 2025 Earnings Slides

Avadel Pharmaceuticals — Q1 2025 Earnings Presentation on 6ix